Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaspect open-label extension of lampalizumab for geographic atrophy secondary to age-related macular degeneration
NL-OMON46297Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of lampalizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Roche. Primary endpoints: Incidence and severity of ocular adverse events and Incidence and severity of systemic adverse events. Started Aug 2017; status: active, not recruiting.
02
Drugs
lampalizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON46297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46297.